Prevention of bone metastases and management of bone health in early breast cancer

Treatment options for women with early-stage breast cancer have never been better, and the addition of bisphosphonates to adjuvant therapy is a valuable new tool capable of substantially improving clinical outcomes for these women. Several recent studies demonstrated that the anticancer activity of bisphosphonates is not limited to bone, and can translate into a reduction in disease recurrence, including reductions in locoregional and distant metastases. In addition, bisphosphonates maintain bone health during adjuvant therapy; this may be especially important for women who are at high risk for fracture.

• Publication year

  2010

• Venue

  Breast Cancer Research

• Publication date

  2010-12-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/bcr2768PMID 21172067PMCID 3046430
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients.

  2012cited by this paper
• Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results.

  2010cited by this paper
• Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

  2010cited by this paper
• Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.

  2010cited by this paper
• Oral bisphosphonate use and breast cancer incidence in postmenopausal women.

  2010cited by this paper
• Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

  2010influential reference
• The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

  2010cited by this paper
• Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.

  2010cited by this paper
• Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer.

  2010influential reference
• Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment.

  2010cited by this paper
• Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk

  2010cited by this paper
• Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients.

  2009cited by this paper
• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  2009cited by this paper
• Use of bisphosphonates and risk of postmenopausal breast cancer.

  2009cited by this paper
• Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

  2009cited by this paper
• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  2009cited by this paper
• The Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The Z-FAST Study 5-Year Final Follow-Up.

  2009cited by this paper
• Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes

  2009cited by this paper
• Efficient Killing of Human Colon Cancer Stem Cells by γδ T Lymphocytes1

  2009cited by this paper
• Practical guidance for the management of aromatase inhibitor-associated bone loss.

  2008influential reference
• Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

  2008cited by this paper
• The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance

  2008influential reference
• Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

  2008cited by this paper
• Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.

  2008cited by this paper
• Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

  2008cited by this paper
• Disseminated Tumor Cells of Breast Cancer Patients: A Strong Prognostic Factor for Distant and Local Relapse

  2008cited by this paper
• The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites

  2008cited by this paper
• [Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study].

  2008cited by this paper
• Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

  2008cited by this paper
• OC11. Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II)

  2008cited by this paper
• Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow

  2008cited by this paper
• Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

  2008cited by this paper
• Meta-analysis of clodronate and breast cancer survival

  2007cited by this paper
• Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.

  2007cited by this paper
• Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club

  2007cited by this paper
• Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

  2006cited by this paper
• The Problem of Cancer Dormancy: Understanding the Basic Mechanisms and Identifying Therapeutic Opportunities

  2006cited by this paper
• Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.

  2006cited by this paper
• Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

  2005cited by this paper
• A pooled analysis of bone marrow micrometastasis in breast cancer.

  2005cited by this paper
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

  2005cited by this paper
• Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.

  2005cited by this paper
• Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients

  2004cited by this paper
• Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

  2003cited by this paper
• American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.

  2003cited by this paper
• Metastasis: Dissemination and growth of cancer cells in metastatic sites

  2002cited by this paper
• Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.

  2001cited by this paper
• Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.

  2001cited by this paper
• Reduction in new metastases in breast cancer with adjuvant clodronate treatment.

  1998cited by this paper
• Skeletal complications of malignancy

  1997cited by this paper

• Determination and clinical features of bone pseudoprogression in metastatic breast cancer

  2025cites this paper
• Computed tomography-based structural rigidity analysis can assess tumor- and treatment-induced changes in rat bones with metastatic lesions

  2024cites this paper
• Bridging the gap — Establishing a dental-oncology service in a cancer centre

  2024influential citation
• Biomarkers and Treatment Strategies for Breast Cancer Recurrence.

  2023cites this paper
• The low and disproportionate utilization of antiresorptive therapy in patients with osseous metastasis

  2023cites this paper
• Targeting of radioactive platinum-bisphosphonate anticancer drugs to bone of high metabolic activity

  2020cites this paper
• Fibroblast growth factor receptors and their inhibitors in preclinical models of breast cancer and bone metastasis

  2019cites this paper
• Cancer-educated mesenchymal stem cells promote the survival of cancer cells at primary and distant metastatic sites via the expansion of bone marrow-derived-PMN-MDSCs

  2019cites this paper
• Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer

  2018cites this paper
• Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer.

  2018cites this paper
• Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy

  2018cites this paper
• Osteoporosis Recovery by Antrodia camphorata Alcohol Extracts through Bone Regeneration in SAMP8 Mice

  2016cites this paper
• Остеопороз у больных раком молочной железы

  2016cites this paper
• Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence

  2015cites this paper
• Bone Metastases

  2014cites this paper
• Bisphosphonates in Bone Metastatic Setting

  2014cites this paper
• Pathways to Breast Cancer Recurrence

  2013cites this paper
• Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells

  2013cites this paper
• Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate!

  2013cites this paper
• Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations.

  2012cites this paper
• Association between CYP2C8 (rs1934951) Polymorphism and Bisphosphonate-Related Osteonecrosis of the Jaws in Patients on Bisphosphonate Therapy: A Meta-Analysis

  2012cites this paper
• Bisphosphonates and oral health: primer and an update for the practicing surgeon.

  2011cites this paper